Results 231 to 240 of about 37,077 (282)

Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: <i>m</i>/<i>z</i> Features and Concordance with Immunofixation Electrophoresis. [PDF]

Biomedicines
Pello R, Iglesias MÁ, Vidal R, Mateos R, Outón M, Agulló C, Varo N, Blanco-Sánchez A, López-Muñoz N, García Á, Miras F, Iñiguez R, Gil-Alós D, Alonso R, López EA, Martínez-López J, Cedena MT.   +16 more
europepmc   +1 more source

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. [PDF]

Cancer Chemother Pharmacol
Hudson A, Jayaram A, Garmezy B, Zorko NA, Zarrabi KK, Mathews L, Rupnow B, Li M, Ghosh D, Urtishak K, Francis P, Wang SC, Attiyeh E, de Bono J.   +13 more
europepmc   +1 more source

Engineering Bispecific Peptides for Precision Immunotherapy and Beyond. [PDF]

Int J Mol Sci
Ding X, Li Y.
europepmc   +1 more source

Special Issue: Antibody Therapy for Hematologic Malignancies. [PDF]

Int J Mol Sci
Butchar JP.
europepmc   +1 more source

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source

Acute lymphoblastic B‐cell leukemia or CAR‐T cell related skin changes – a relevant diagnostic challenge

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 256-258, February 2026.
Farzan Solimani, Amrei Dilling, Konrad Heisterkamp, Frederik Damm, Olaf Penack, Christian Oberender, Philipp Le‐Coutre, Martina Rudelius, Kamran Ghoreschi, Alexander Nast   +9 more
wiley   +1 more source

Linvoseltamab in multiple myeloma: a BCMA × CD3 bispecific antibody for relapsed and refractory disease. [PDF]

Ann Med Surg (Lond)
Khan G, Haider E, Imtiaz A, Ekouo J.
europepmc   +1 more source

Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas. [PDF]

J Transl Med
Zhang MY, Cai YM, Zhu XQ, Lu KJ, Shen LJ, Du J.   +5 more
europepmc   +1 more source

Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. [PDF]

Pharmaceutics
Susilo ME, Schaller S, Jiménez-Franco LD, Kulesza A, de Witte WEA, Chen SC, Boswell CA, Mandikian D, Li CC.   +8 more
europepmc   +1 more source

Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges. [PDF]

Front Immunol
Wang Y, Wang B, Liu S, Chen Y, Zhang S, Bu L, Zhu W, Liu X, Sun P.   +8 more
europepmc   +1 more source